An osteogenic microenvironment improves response during denosumab treatment in giant cell tumors of bone in the spine.
9 affiliations
- 1Materials Engineering, University of British Columbia, Vancouver, BC, Canada.
- 2Centre for Aging SMART, Vancouver, BC, Canada.
- 3Vancouver Prostate Centre, Vancouver, BC, Canada.
- 4Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
- 5Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
- 6Department of Neurosurgery, The Warren Alpert Medical School of Brown University, Providence, RI, United States.
- 7Department of Neurosurgery, Rhode Island Hospital, Providence, RI, United States.
- 8Combined Neurosurgical and Orthopaedic Spine Program, Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada.
- 9School of Biomedical Engineering, University of British Columbia, Vancouver, BC, Canada.
Abstract
Introduction
Giant cell tumors of bone are benign but locally aggressive tumors. Typically diagnosed in individuals between the ages of 20 and 40 years, these tumors cause significant amounts of pain, and morbidity. Giant cell tumors of bone can be treated with an increased dosing regimen of denosumab, a monoclonal antibody that targets receptor activator of nuclear kappa-B ligand, which has shown promise in reducing pain and tumor size, while contributing to improved ossification of the tumor. However, the ossification response observed varies, with some patients responding rapidly with total tumor ossification, while others respond slowly, if at all. Due to gaps in our current understanding of what improves ossification in patients, we aimed to identify patient specific biomarkers that contributed to increased ossification in our patient cohort.Methods
Pre-treatment biopsy samples from 19 patients collected from 3 North American centres were grouped based on their response to denosumab, determined from their change in Boriani ossification grade after treatment. The 19 patients pre-treatment tissue was used in gene expression analysis using RNA extraction and nanoString analysis. A subset of tissue from 6 patients and 3 healthy controls were included in protein expression analysis, where differential expression and gene set enrichment analysis was conducted to identify upregulated proteins and pathways contributing to the different treatment responses.Results
A distinct microenvironment was identified through both genetic and proteomic expression. Good responders demonstrated upregulation of TNFRSF11B and CX3CL1, genes that are related to bone remodeling, and a downregulation of CX3CR1. Additionally, tissue remodeling and cell proliferation markers were upregulated, while immune related markers were downregulated in our good responders (increased ossification of tumor). Genetic analysis was complemented by protein analysis which in our good responders demonstrated upregulation of bone pathways associated with bone development, bone mineralization, ossification, and osteoblast differentiation, and downregulation in bone remodeling, bone resorption, and osteoclast differentiation. Further analysis identified upregulation of LTF, FBLN5, LOX, CHAD, and OGN, and downregulation of CEBPB, CTSK, and TFRC.Discussion
Giant cell tumors of bone show varied mineralization responses to denosumab, with the biological factors associated with this variability remaining poorly understood. We used gene and protein expression analysis of pre-treatment biopsy tissue to compare good and poor mineralization responses. The good responders demonstrate a pre-treatment tumor microenvironment that favors bone formation and reduced resorption, suggesting that biomarker analysis of biopsied samples may help to understand a patient's response to denosumab and guide personalized treatment strategies.
Related
- Porous Ti6Al4V as an Osteogenic Microenvironment? A Perspective From Architecture-Matched In Vitro Studies
- Bladder cancer immune microenvironment: immune-cell distribution, disease associations, treatment remodeling, and baseline immune features associated with treatment response and prognosis
- In vitro evaluation of the osteogenic associated cellular response and antibacterial activities of Vitex negundo leaf aqueous extract
- Pretreatment bone turnover status and long-term bone mineral density response to denosumab
- Dissociated skeletal response to first-line immunotherapy in synchronous bone metastatic non-small cell lung cancer patients: Clinical profiles and survival benefit of denosumab adjunction
BibTeX
@article{birch2026osteogenic,
title = {{An osteogenic microenvironment improves response during denosumab treatment in giant cell tumors of bone in the spine.}},
author = {Robyn Birch and Felipe Eltit and Tony Ng and Laurence D Rhines and Ziya L Gokaslan and Nicolas Dea and Charles G Fisher and Michael E Cox and Rizhi Wang and Raphaële Charest-Morin},
journal = {Frontiers in medicine},
year = {2026},
month = oct,
doi = {10.3389/fmed.2026.1919109},
url = {https://europepmc.org/article/MED/42922809},
note = {CC BY},
}
RIS
TY - JOUR
TI - An osteogenic microenvironment improves response during denosumab treatment in giant cell tumors of bone in the spine.
AU - Robyn Birch
AU - Felipe Eltit
AU - Tony Ng
AU - Laurence D Rhines
AU - Ziya L Gokaslan
AU - Nicolas Dea
AU - Charles G Fisher
AU - Michael E Cox
AU - Rizhi Wang
AU - Raphaële Charest-Morin
PY - 2026
DA - 2026/10/08
JO - Frontiers in medicine
DO - 10.3389/fmed.2026.1919109
UR - https://europepmc.org/article/MED/42922809
AB - Introduction Giant cell tumors of bone are benign but locally aggressive tumors. Typically diagnosed in individuals between the ages of 20 and 40 years, these tumors cause significant amounts of pain, and morbidity. Giant cell tumors of bone can be treated with an increased dosing regimen of denosumab, a monoclonal antibody that targets receptor activator of nuclear kappa-B ligand, which has shown promise in reducing pain and tumor size, while contributing to improved ossification of the tumor. However, the ossification response observed varies, with some patients responding rapidly with total tumor ossification, while others respond slowly, if at all. Due to gaps in our current understanding of what improves ossification in patients, we aimed to identify patient specific biomarkers that contributed to increased ossification in our patient cohort.Methods Pre-treatment biopsy samples from 19 patients collected from 3 North American centres were grouped based on their response to denosumab, determined from their change in Boriani ossification grade after treatment. The 19 patients pre-treatment tissue was used in gene expression analysis using RNA extraction and nanoString analysis. A subset of tissue from 6 patients and 3 healthy controls were included in protein expression analysis, where differential expression and gene set enrichment analysis was conducted to identify upregulated proteins and pathways contributing to the different treatment responses.Results A distinct microenvironment was identified through both genetic and proteomic expression. Good responders demonstrated upregulation of TNFRSF11B and CX3CL1, genes that are related to bone remodeling, and a downregulation of CX3CR1. Additionally, tissue remodeling and cell proliferation markers were upregulated, while immune related markers were downregulated in our good responders (increased ossification of tumor). Genetic analysis was complemented by protein analysis which in our good responders demonstrated upregulation of bone pathways associated with bone development, bone mineralization, ossification, and osteoblast differentiation, and downregulation in bone remodeling, bone resorption, and osteoclast differentiation. Further analysis identified upregulation of LTF, FBLN5, LOX, CHAD, and OGN, and downregulation of CEBPB, CTSK, and TFRC.Discussion Giant cell tumors of bone show varied mineralization responses to denosumab, with the biological factors associated with this variability remaining poorly understood. We used gene and protein expression analysis of pre-treatment biopsy tissue to compare good and poor mineralization responses. The good responders demonstrate a pre-treatment tumor microenvironment that favors bone formation and reduced resorption, suggesting that biomarker analysis of biopsied samples may help to understand a patient's response to denosumab and guide personalized treatment strategies.
SN - 2296-858X
ER -